SOLV Solventum

Q3 2025 10-Q

Filed: Nov 6, 2025Period ending Sep 30, 2025

Health Care

Surgical & Medical Instruments & ApparatusSEC EDGAR

Solventum (SOLV) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Total revenue $2,096M Q3 2025, up 0.7% YoY from $2,082M Q3 2024, organic growth 2.7%, adjusted for divestitures and currency
• Operating margin 80.6% Q3 2025 vs 13.2% Q3 2024, driven largely by $1.5B gain on sale of Purification and Filtration business

+4 more insights

Risk Factors

• No new or changed risk factors since 2024 10-K
• Continued risks from supply chain disruptions impacting production timelines

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$2.1B

▲ +0.7% YoY▼ -3.0% QoQ

Net Income

$1.3B

▲ +937.7% YoY▲ +1306.7% QoQ

Net Margin

60.4%

▲ +5454bp YoY▲ +5624bp QoQ

Source: XBRL data from Solventum Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Solventum

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.